Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds
The DOI matches its Crossref record.
Abstract
Drug-induced liver injury is the most common cause of market withdrawal of pharmaceuticals, and thus, there is considerable need for better prediction models for DILI early in drug discovery. We present a study involving 223 marketed drugs (51% associated with clinical hepatotoxicity; 49% non-hepatotoxic) to assess the concordance of in vitro bioactivation data with clinical hepatotoxicity and have used these data to develop a decision tree to help reduce late-stage candidate attrition. Data to assess P450 metabolism-dependent inhibition (MDI) for all common drug-metabolizing P450 enzymes were generated for 179 of these compounds, GSH adduct data generated for 190 compounds, covalent binding data obtained for 53 compounds, and clinical dose data obtained for all compounds. Individual data for all 223 compounds are presented here and interrogated to determine what level of an alert to consider termination of a compound. The analysis showed that 76% of drugs with a daily dose of <100 mg were non-hepatotoxic (p < 0.0001). Drugs with a daily dose of ≥100 mg or with GSH adduct formation, marked P450 MDI, or covalent binding ≥200 pmol eq/mg protein tended to be hepatotoxic (∼ 65% in each case). Combining dose with each bioactivation assay increased this association significantly (80-100%, p < 0.0001). These analyses were then used to develop the decision tree and the tree tested using 196 of the compounds with sufficient data (49% hepatotoxic; 51% non-hepatotoxic). The results of these outcome analyses demonstrated the utility of the tree in selectively terminating hepatotoxic compounds early; 45% of the hepatotoxic compounds evaluated using the tree were recommended for termination before candidate selection, whereas only 10% of the non-hepatotoxic compounds were recommended for termination. An independent set of 10 GSK compounds with known clinical hepatotoxicity status were also assessed using the tree, with similar results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Shuhendler, A. J., Pu, K., Cui, L., Uetrecht, J. P., & Rao, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2838 · Cited by 623
Chen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
Drug-induced liver injury: a comprehensive review
Hosack, T., Damry, D., & Biswas, S. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231163410 · Cited by 214
Vorrink, S. U., Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy058 · Cited by 187
Lauschke, V. M., Shafagh, R. Z., Hendriks, D. F. G., & Ingelman‐Sundberg, M. (2019) · Biotechnology Journal · doi:10.1002/biot.201800347 · Cited by 153
Metadata
- Authors
- Sakatis, M. Z., Reese, M. J., Harrell, A. W., Taylor, M. A., Baines, I. A., Chen, L., Bloomer, J. C., Yang, E. Y., Ellens, H. M., Ambroso, J. L., Lovatt, C. A., Ayrton, A. D., & Clarke, S. E.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-09-19
- Volume
- 25
- Issue
- 10
- Pages
- 2067-2082
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W1992890364
- Cited by
- 121
- References
- 0
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds. https://app.cochat.ai/papers/10.1021/tx300075j
- The paper
- Sakatis, M. Z., Reese, M. J., Harrell, A. W., Taylor, M. A., Baines, I. A., Chen, L., Bloomer, J. C., Yang, E. Y., Ellens, H. M., Ambroso, J. L., Lovatt, C. A., Ayrton, A. D., & Clarke, S. E. (2012). Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds. Chemical Research in Toxicology. https://doi.org/10.1021/tx300075j
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.